Developing as a noteworthy advance in the struggle against obesity, the drug is capturing considerable attention . This treatment combines effects of two recognized GLP-1 receptor agonists, dulaglutide , and an new glucose-dependent peptide component. Early study findings have indicated impressive fat loss in people with obesity , potentially prov